Physician profile
David Cessar
NPI 1851912810
$1,364.96
in general payments reported to CMS, 2019-2025
18 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $468 · 2022: $339 · 2023: $25.21 · 2024: $280 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $558.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $222.03 | 2021-2022 | |
| Intrinsic Therapeutics | $194.13 | 2022 | |
| Providence Medical Technology, INC. | $176.04 | 2022-2024 | |
| Cerapedics INC. | $139.31 | 2021 | |
| Novo Nordisk INC | $124.00 | 2021 | |
| Boston Scientific Corporation | $118.15 | 2023-2025 | General - Dbs |
| Abbott Laboratories | $74.85 | 2024-2025 | Eterna |
| Alexion Pharmaceuticals, INC. | $51.12 | 2025 | Ultomiris |
| Lilly USA, LLC | $36.81 | 2025 | Kisunla |
| Orthofix Medical, INC. | $35.13 | 2024-2025 | Spinal-Stim, Cervical-Stim |
| Highridge Medical LLC | $34.66 | 2024 | Biomet Spinalpak Non-Invasive Spine Fusion Stimulator System |
| Vertex Pharmaceuticals Incorporated | $31.98 | 2025 | |
| Next Science LLC | $28.67 | 2024 | Xperience, Surgx, Blastx |
| Azurity Pharmaceuticals, INC. | $24.79 | 2025 | Horizant |
| Averitas Pharma INC. | $23.77 | 2024 | Qutenza |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $19.25 | 2024 | Matrixneuro |
| Pfizer INC. | $16.69 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $13.58 | 2024 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cessar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.